Vancouver, BC, January17, 2019 – INVICTUS MD STRATEGIES CORP. (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announced that it has submitted its application to list its common shares on the NASDAQ Capital Market. In advance of listing on NASDAQ, the Company will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company’s Shares on NASDAQ remains subject to the approval of NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the effectiveness of the Form 40-F Registration Statement.

Subject to approval for listing, it is anticipated that the Company’s Shares, including the existing Shares trading on the OTCQX under the ticker symbol “IVITF”, will trade on NASDAQ under the ticker symbol “INV”. The Company’s Shares will continue to trade on the TSXV under the ticker symbol “GENE” and on the Frankfurt Stock Exchange under the ticker symbol “8IS1”. A trading date will be made public once all regulatory formalities are satisfied.

In connection with the listing on NASDAQ, the Company also announces it will be proceeding with a consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Share for every seven pre-Consolidation Shares.  No fractional Shares will be issued.  Any fractional Share will be rounded down to the nearest whole number.

The Consolidation is subject to final confirmation by the TSX Venture Exchange.  As a result of the Consolidation, the 112,176,712 Shares which are currently issued and outstanding will be reduced to approximately 16,025,244 Shares, subject to rounding.

Leave a comment